Semaglutide is a GLP-1 (glucagon-like-peptide-1) receptor agonist
Compounded versions require patients to draw precise amounts from vials, which has led to reported administration errors where patients accidentally injected doses up to 10 times higher than prescribed, causing severe nausea, vomiting, abdominal pain, and weakness
These costs will be available to self-pay patients through more than 70,000 pharmacies nationwide, as well as via home delivery and certain telehealth providers
However, GI side effects are common during titration, with nausea, vomiting, and diarrhea increasing at higher doses, and discontinuation rates as high as 25% at the 15 mg level
Mounjaro, another brand name for semaglutide, has gained recognition as a valuable medication for managing type 2 diabetes